Previous studies have shown that statins effectively reduce Keratin 6A (KRT6A) gene promoter activity, leading to their use as a first-line treatment for pachyonychia congenita, a rare skin disorder linked to KRT6A [52]. Here, KRT6A is linked to pachyonychia congenita.